T A B L E O F C O N T E N

Main results
A total of 1912 children were enrolled from seven studies. Data interpretation was limited by the inability to extract data that referred to children with M. pneumoniae. In most studies, clinical response did not differ between children randomised to a macrolide antibiotic and children randomised to a non-macrolide antibiotic. In one controlled study (of children with recurrent respiratory infections, whose acute LRTI was associated with Mycoplasma, Chlamydia or both by polymerase chain reaction, and/or paired sera) 100% of children treated with azithromycin had clinical resolution of their illness compared to 77% not treated with azithromycin at one month.
Authors' conclusions
There is insufficient evidence to draw any specific conclusions about the efficacy of antibiotics for this condition in children (although one trial suggests macrolides may be efficacious in some children with LRTI secondary to Mycoplasma). The use of antibiotics has to be balanced with possible adverse events. There is still a need for high quality, double-blinded RCTs to assess the efficacy and safety of antibiotics for LRTI secondary to M. pneumoniae in children.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics to treat community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children
Mycoplasma pneumoniae (M. pneumoniae) is a bacterial infection often responsible for lower respiratory tract infections (LRTI) in children. The infection can present in a number of different ways and the most common respiratory manifestations are acute bronchitis, pneumonia or wheezing. The illness is generally self-limiting with symptoms that can last several weeks but may (occasionally) also cause severe pneumonia. Antibiotics are often given to children with M. pneumoniae LRTI. We found seven studies (1912 children) but could not extract relevant data relating to efficacy or adverse events. Thus there is still insufficient evidence to show conclusively that antibiotics are effective in children with LRTI caused by M. pneumoniae.
B A C K G R O U N D Description of the condition
Mycoplasma pneumoniae (M. pneumoniae) is widely recognised as an important cause of community-acquired lower respiratory tract infection (LRTI) in children, accounting for 14% to 34% of cases 
Description of the intervention
Antibiotics are frequently used to treat LRTI and empiric antibiotic therapy is often chosen to cover both bacteria and atypical organisms (Kogan 2003). A review of several major textbooks offers conflicting advice for management of M. pneumoniae LRTI. The chapter on M. pneumoniae in a paediatric respiratory textbook (Phelan 1994) mentions that there is little evidence of beneficial effect from antibiotic therapy. This is in contrast to the recommendations in a major general paediatric textbook (Rudolph 2003) and paediatric infectious disease textbook (Katz 1998) which state that erythromycin is the treatment of choice.
How the intervention might work
The use of antibiotics in treating LRTI in children would be expected to reduce the severity or duration (or both) of the infection and its associated symptoms. 
Why it is important to do this review
O B J E C T I V E S
To determine whether antibiotics are effective in the treatment of childhood LRTI secondary to M. pneumoniae infections acquired in the community.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing antibiotics from the macrolide, tetracycline or quinolone class (i.e. antibiotics that are efficacious for mycoplasma) versus placebo, or antibiotics from any other class (i.e. medications that are not efficacious for mycoplasma).
Types of participants
Trials that included children under 18 years of age with community-acquired LRTI secondary to M. pneumoniae. Diagnosis of M. pneumoniae infection was via either a four-fold rise in total antibody titre from paired sera or total antibody titre ≥ 1:512 on a single specimen. We included other methods of diagnosis, such as culture or PCR of M. pneumoniae in nasopharyngeal secretions or demonstration of elevated IgM on a single specimen (IgM titre ≥ 1:10), and analysed these separately as a subgroup.
Exclusion criteria
1. Children with underlying chronic cardiorespiratory illnesses, such as cystic fibrosis, bronchiectasis, immunodeficiency, chronic neonatal lung disease and symptomatic congenital heart disease.
2. Children with non-community acquired LRTI.
Types of interventions
We evaluated two separate treatment regimes. 1. Any antibiotic versus placebo. 2. Antibiotics from the macrolide, tetracycline or quinolone class versus placebo or antibiotics from any other class. We included trials that allowed the use of other medications or interventions in addition to antibiotic therapy if all participants had equal access to such medications or interventions.
Types of outcome measures
We made attempts to obtain data on at least the following outcome measures.
Primary outcomes
1. Proportions of participants who were not improved at follow up. Failure to improve was measured according to the hierarchy listed below.
Secondary outcomes
1. Mean difference in symptoms and signs (mean improvement in clinical state).
2. Proportions requiring hospitalisation. 3. Proportions experiencing pulmonary complications (empyema, pleural effusion, air leak).
4. Proportions experiencing non-pulmonary complications. 5. Proportions experiencing adverse effects (for example, nausea, diarrhoea, abdominal pain, rash).
6. Proportions experiencing complications (for example, requirement for medication change). The proportions of participants who failed to improve on treatment and the mean clinical improvement were determined using the following hierarchy of assessment measures. All outcomes were reported but where two or more assessment measures were reported in the same study and conflicting results were obtained, we used the outcome measure that was listed first in the hierarchy.
1. 
Searching other resources
We checked all references for reports of trials.
Data collection and analysis
Selection of studies
The review authors (JG, AC, SM) independently reviewed literature searches from the title, abstract or descriptions, to identify potentially relevant trials for full review. Searches of bibliographies and texts were conducted to identify additional studies. The review authors (JG, AC, SM) independently selected trials for inclusion from the full text using specific criteria.
Data extraction and management
The review authors (JG, AC, SM) independently extracted data and resolved disagreement by consensus. We reviewed trials that satisfied the inclusion criteria and recorded the following information: study setting; year of study; source of funding; patient recruitment details (including number of eligible children); inclusion and exclusion criteria; randomisation and allocation concealment method; numbers of participants randomised; blinding (masking) of participants, care providers and outcome assessors; intervention (type of anti-microbials, dose, duration); control (type, dose, duration); co-interventions; numbers of patients not followed up; reasons for withdrawals from study protocol (clinical, side effects, refusal and other); details on side effects of therapy; and whether intention-to-treat (ITT) analyses were possible. We extracted data on the outcomes described previously. The review authors requested further information from the study authors where required.
Assessment of risk of bias in included studies
In the original review (Gavranich 2005a) the review authors (JG, AC) utilised the Jadad and quality assessment scores. With this update, the review authors (JG, AC, SM) independently assessed the quality of studies included in the review using the 'Risk of bias' 2. Allocation concealment. This assesses whether or not enrolling staff were aware of the group to which participants would be allocated.
3. Blinding. This assesses the extent of blinding, with participant/caregiver and outcome assessor blinding taken into account.
4. Follow up. This assesses whether the proportion of participants lost to follow up is admissible, and whether adequate reasons for the losses were made available.
5. Reporting of participants by allocation group. This assesses whether the results were reported relative to the treatment groups.
Measures of treatment effect
In the protocol we planned to calculate relative and absolute risk reductions using an ITT analysis for the dichotomous outcome variables of each individual study. However, data were unavailable.
Dealing with missing data
The review authors wrote to the trial authors to enquire about availability of data but we did not receive any replies.
Assessment of heterogeneity
In the protocol we planned to describe any heterogeneity between the study results and, depending upon the number of trials included in the review, a funnel plot was planned to look for publication bias. However, data were unavailable and no studies were included in a meta-analysis.
Data synthesis
In the protocol we planned to include the results from studies that met the inclusion criteria and report any of the outcomes of interest in the subsequent meta-analysis. We planned to calculate the summary weighted risk ratio and 95% confidence interval (CI) (fixed-effect model) using the inverse of the variance of each study result for weighting (Cochrane statistical package, Review Manager 4.2). We planned to calculate the number needed to treat using the summary odds ratio and the average control event rate described in the relevant studies. We stated in the protocol that the cough indices were assumed to be normally distributed continuous variables so the mean difference in outcomes could be estimated (weighted mean difference). In studies that reported outcomes using different measurement scales, the standardized mean difference would be estimated. However, data were unavailable.
Subgroup analysis and investigation of heterogeneity
In the protocol we intended to perform an a priori subgroup analysis for the following.
1. Children aged seven years and older. 2. Intervention type (class of antibiotics). 3. Diagnostic criteria used for identification of M. pneumoniae. However, data were unavailable.
Sensitivity analysis
In the protocol we planned a sensitivity analysis to assess the impact of the potentially important factors on overall outcomes.
1. Study quality. 2. Study size. 3. Variation in the inclusion criteria. 4. Differences in the medications used and duration of treatment in the intervention and comparison groups.
5. Differences in outcome measures.
6. Analysis by 'treatment received' rather than ITT. However, data were unavailable.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies.
Results of the search
The initial search identified 91 potentially relevant titles. After reviewing the abstracts, we obtained 17 papers in full text for consideration for inclusion into the review. We included seven studies and details are provided in the Characteristics of included studies table. Three of the included studies were non-English: German (Ruhrmann 1982) and Spanish (Gomez Campdera 1996; Saez-Llorens 1998). 
Included studies Participants
The studies involved children diagnosed with LRTI ranging in age from one month to 16 years. In all except three studies (Esposito 2005; Gomez Campdera 1996; Soderstrom 1991) children had pneumonia supported with abnormal chest X-ray and apart from two studies (Esposito 2005; Ruhrmann 1982) the children were described as having community-acquired pneumonia. The study by Gomez Campdera 1996 did not define pneumonia and the study by Soderstrom 1991 included participants with acute bronchitis. The number of children with M. pneumoniae causing LRTI was not stated in four studies (Esposito 2005; Gomez Campdera 1996; Ruhrmann 1982; Saez-Llorens 1998). In one study (Wubbel 1999) there were 12 children with M. pneumoniae infections and six were in the subgroup randomised to either azithromycin or amoxycillin-clavulanate, but the number assigned to each therapy was not available. In two other studies the number of children with M. pneumoniae infections in each intervention group was provided. In the study by Harris 1998 there were 30 children who had M. pneumoniae infections randomised to either azithromycin or amoxycillin-clavulanate (21 in azithromycin group and nine in amoxycillin-clavulanate group) and there were eight children in the study by Kogan 2003 (five in the azithromycin group and three in the amoxycillin-clavulanate group). In the study by Soderstrom 1991 there were only seven patients with LRTI (bronchitis) and one case of M. pneumoniae, but the age of the participants with M. pneumoniae was not provided. The study by Esposito 2005 did not distinguish between upper and lower respiratory tract infections in their analysis of results, although the number of M. pneumoniae infections (which included both URTIs and LRTIs) was made available.
Interventions
Studies included in this review involved patients with LRTI randomised to either a macrolide antibiotic or another antibiotic, usually a different macrolide or non-macrolide antibiotic. In two studies (Ruhrmann 1982; Soderstrom 1991) the entire study population was randomised to either a macrolide or non-macrolide antibiotic. Ruhrmann 1982 included children with pneumonia who received either erythromycin 70 to 80 mg/kg/day or amoxycillin 60 to 70 mg/kg/day. The duration of therapy was not stated. The study by Soderstrom 1991 had a subgroup of participants (number of children not stated) with acute bronchitis who received either erythromycin 500 mg twice daily for seven days or phenoxymethylpenicillin 800 mg twice daily for seven days. Four studies (Gomez Campdera 1996; Harris 1998; Saez-Llorens 1998; Wubbel 1999) randomised a subgroup of children under five years of age to azithromycin or amoxycillin-clavulanate. The dose of amoxycillin-clavulanate was 40 mg/kd/day in three divided doses for 10 days in all studies. The dose of azithromycin was 10 mg/kg once daily for three days in one study (Gomez Campdera 1996) and 10 mg/kg on day one followed by 5 mg/kg once daily for day two to five in three studies (Harris 1998; Saez-Llorens 1998; Wubbel 1999). In the study by Kogan 2003 the intervention for the subgroup with classic pneumonia was either azithromycin 10 mg/kg once daily for three days or amoxycillin 75 mg/kg/day in three divided doses for seven days. The Esposito 2005 study compared azithromycin with symptom-specific agents to symptomspecific agents alone; the azithromycin that was given was 10 mg/ kg/day, three days per week for three weeks and acetaminophen (at 10 mg/kg/dose) was the symptom-specific agent.
Outcome measures
Clinical
Clinical response was the main outcome but was not defined in three studies (Gomez Campdera 1996; Ruhrmann 1982; Soderstrom 1991). In three studies clinical cure was defined as complete resolution of symptoms and signs by day 15 to 19 (Harris 1998), day 10 to 25 (Saez-Llorens 1998) and day 10 to 37 (Wubbel 1999). In the study by Kogan 2003 the clinical response was defined as the proportion of children without fever on day three. The Esposito 2005 study evaluated clinical responses at both one month (defined as the complete resolution of the acute symptoms, with no relapse) and six months (defined as the presence of no more than two respiratory relapses). 1999) where the number of children with LRTI due to M. pneumoniae was not identified, but no reply was received at the time this review was completed.
Radiological
Radiological outcome was recorded in three studies (Gomez Campdera 1996; Harris 1998; Kogan 2003) but was not defined in the study by Gomez Campdera 1996. Bacteriological outcome was recorded in three studies (Esposito 2005; Harris 1998; Saez-Llorens 1998) but was not defined in the study by Saez-Llorens 1998. Adverse events were recorded by four studies (Gomez Campdera 1996; Harris 1998; Saez-Llorens 1998; Wubbel 1999) and were only defined in the study by Harris 1998. We made attempts to obtain individual patient data from four studies (Esposito 2005; Harris 1998; Kogan 2003; Wubbel
Excluded studies
We excluded 10 papers and details are provided in the Characteristics of excluded studies table 
Risk of bias in included studies
We assessed risk of bias using the 'Risk of bias' tables (Higgins 2009). We generated a graph and summary for the information, and the combined results for the different categories of risk are highlighted. Approximately 50% of included studies were not blinded, but good results were seen for both follow up and reporting of participants by allocation group overall (i.e. in more than half the included studies these were not found to be a source of bias).
Allocation
All studies were described as randomised and the method of randomisation was clearly described and appropriate in three studies (Esposito 2005; Ruhrmann 1982; Saez-Llorens 1998) where a random number list was used. The method of randomisation was unclear in one study (Wubbel 1999) where the method used was described as a list of randomised therapy assignments. In the trial Soderstrom 1991 the method used was sequential patient numbers and this was thought to be inadequate. Three studies (Gomez Campdera 1996; Harris 1998; Kogan 2003) did not describe the method of randomisation. Concealment of allocation was unclear in all except three studies; two (Saez-Llorens 1998; Wubbel 1999) assigned therapy by pharmacy, and one (Esposito 2005) allocated the duties of enrolment and randomisation to separate investigators.
Blinding
There
Incomplete outcome data
Five of the included studies adequately followed up their participants. Three of the eight included studies had unclear levels of follow up. Gomez Campdera 1996 and Ruhrmann 1982 made no mention of losses to follow up. While Saez-Llorens 1998 mentioned that 30 were lost to follow up, there was no mention of why or from which groups these losses occurred.
Selective reporting
Although selective reporting was not readily identified, possible issues are highlighted in 'Other potential sources of bias'.
Other potential sources of bias
Three of the eight included studies (Esposito 2005; Harris 1998; Wubbel 1999) were funded by Pfizer Incorporated, a large pharmaceutical company responsible for producing Zithromax, a popular azithromycin. This association may have influenced the subjective outcome measures of these studies (i.e. 'clinical success'). All three studies were concerned with the efficacy of azithromycin in treating LRTIs, and none found it to be a less effective drug than alternative antimicrobial therapy. Wubbel 1999 found no difference and Esposito 2005 and Harris 1998 found it to be a superior treatment.
Effects of interventions
There were 1912 children enrolled from seven studies. The number of children from one study (Soderstrom 1991) was unavailable.
Data interpretation was significantly limited by the inability to extract data that specifically referred to children with LRTI caused by M. pneumoniae. There was only one study of children randomised to any antibiotic versus placebo (Esposito 2005). Most of the included studies comprised a subgroup of children who were randomised to a macrolide versus non-macrolide antibiotic. The total number of children in this subgroup was not known as the numbers were only available in four studies (Harris 1998; Kogan 2003; Ruhrmann 1982; Wubbel 1999). The number of children with LRTI secondary to M. pneumoniae in this subgroup was only available in two studies (Harris 1998; Kogan 2003) and the lack of individual patient data did not allow for inclusion of results in a meta-analysis. There was a total of 26 in the azithromycin group and 12 in the amoxycillin-clavulanate group. In the study by Gomez Campdera 1996 the rate of clinical cure was 95.12% in the azithromycin group and 90.41% in the amoxycillin-clavulanate group. Radiological improvement was noted in 90.6% of the azithromycin group. Adverse events were recorded in 11.25% of the azithromycin group and 17.14% in the amoxycillin-clavulanate group. Harris 1998 reported no difference in the rate of clinical cure at day 15 to 19 (67.2% versus 66.7%) and four to six weeks (85.1% versus 85.4%) of children randomised to azithromycin or amoxycillin-clavulanate. M. pneumoniae was identified in 16% (30 of 188 children under five years of age). Eradication of M. pneumoniae occurred in 3/3 in the azithromycin group and in 0/1 in the amoxycillin-clavulanate group. Adverse events in those children under five years of age were 12.1% in the azithromycin group and 42.3% in the amoxycillin-clavulanate group. One participant in each group discontinued treatment because of adverse events. In the study by Kogan 2003 which compared azithromycin to amoxicillin in children with classical pneumonia (eight children of 47 had M. pneumoniae), X-ray resolution was significantly better in those treated with azithromycin (81% versus 60.9% at day seven) but there was no difference in clinical symptoms or signs between groups. In those with atypical pneumonia (23 children of 59 had M. pneumoniae) there was no significant difference between children treated with azithromycin or erythromycin (Kogan 2003). Ruhrmann 1982 reported clinical cure after 3.79 days in the erythromycin group and 3.96 days in the amoxycillin group. Saez-Llorens 1998 reported a similar clinical response (99% versus 98%) in children under five years who were randomised to azithromycin or amoxycillin-clavulanate. Eradication of M. pneumoniae occurred in 23 out of 24 in the azithromycin group. Adverse events were reported in 11% on azithromycin, 30% on amoxycillin-clavulanate and 27% on erythromycin. Soderstrom 1991 did not report the clinical response in the subgroup of patients with bronchitis. In the study by Wubbel 1999, where 7% (12 of 168 children) had M. pneumoniae, no difference was found in children randomised to azithromycin or amoxicillinclavulanate. Adverse events were reported in 14% on azithromycin, 67% on amoxycillin-clavulanate and 25% on erythromycin.
Eleven patients did not complete the prescribed therapy. Esposito 2005, which grouped C. pneumoniae and M. pneumoniae together (and did not distinguish between upper and lower respiratory tract infections) when reporting clinical success rates (with a total of 200/560 infected children), found a 100% success rate in the short term with azithromycin and symptomatic therapy, and a 73.2% success rate at the six-month follow up. Symptomatic treatment alone showed a success rate of 77.2% at one month and 56.0% at six months. Adverse events were not reported in this study.
D I S C U S S I O N
Summary of main results
This review failed to find any randomised controlled trials (RCTs) which specifically looked at the effectiveness of antibiotics for lower respiratory tract infection (LRTI) secondary to M. pneumoniae. There was only one study of antibiotics versus placebo (Esposito 2005), but this study defined success rates relative to LRTI secondary to M. pneumoniae and Chlamydia defined by polymerase chain reaction (PCR) or paired sera. In this study significantly more children in the azithromycin group had 'clinical success' on follow up than the placebo group. From the other studies, in the subgroup of children with LRTI secondary to M. pneumoniae the intervention was a macrolide antibiotic versus a nonmacrolide antibiotic, usually amoxycillin-clavulanate. This subgroup identified only 38 children with M. pneumoniae infection and there were insufficient data to analyze the efficacy of macrolide antibiotics in this group. Adverse events were common, reported in 11% to 67% of children. The majority of adverse events related to the gastrointestinal tract (diarrhoea, vomiting, abdominal pain, nausea, anorexia) and where reported were more common in younger children (under five years of age).
Overall completeness and applicability of evidence
There were significant difficulties in interpreting the data from the included studies. Firstly, although all studies (except Soderstrom 1991) enrolled children with LRTI, only a proportion had M. pneumoniae infection. It was not possible to obtain information on the subgroup with M. pneumoniae. Secondly, the dose and type of antibiotics differed among studies. Thirdly, application of diagnostic criteria (serology versus PCR) varied and these are not necessarily interchangeable. Fourthly, the inclusion criteria differed (various types of LRTI manifestation) between studies. Furthermore the outcomes measured were variable and in some papers clinical cure was undefined.
Quality of the evidence
In addition to the above, the quality of the studies varied (see Figure 1 ; Figure 2 ) with non-blinded outcomes in the majority of the included studies. 
Potential biases in the review process
No potential biases in the review process were identified.
Agreements and disagreements with other studies or reviews
Despite the commonality of M. pneumoniae LRTI in children (up to 40% of community-acquired pneumonia reported by Waites 2003), there is surprisingly no RCT that has specifically evaluated the efficacy of antibiotics for the treatment of childhood LRTI secondary to M. pneumoniae infections acquired in the community. This is reflected in conflicting advice given in paediatric textbooks (Phelan 1994; Rudolph 2003) and this systematic review has highlighted the need for such studies.
A U T H O R S ' C O N C L U S I O N S Implications for practice
Based on a single RCT, it is likely that macrolides are efficacious in (at least) a small group of children with LRTI secondary to M. pneumoniae. However, there is insufficient evidence to draw any specific conclusions about the efficacy of antibiotics for this condition in children. The use of antibiotics for M. pneumoniae LRTI has to be individualised and balanced with possible adverse events associated with antibiotic use.
Implications for research
M. pneumoniae infection is relatively common and its clinical manifestations range from being asymptomatic to death from complications of M. pneumoniae infection. As respiratory symptoms are the most common symptoms, there is a need for high quality, double-blinded RCTs to assess the efficacy and safety of antibiotics for LRTI secondary to M. pneumoniae in children. Studies should consider the various clinical and microbiological diagnostic criteria of M. pneumoniae infection and utilise clear outcome criteria. Community studies using PCR for rapid early diagnosis would be useful in evaluating the efficacy of antibiotics for M. pneumoniae for respiratory and non-respiratory manifestations as well as for prevention of complications and microbiological clearance of M. pneumoniae.
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Esposito 2005
Methods Participants were recruited from the outpatient clinic of the Institute of Pediatrics, University of Milan, Italy, between November 2000 and March 2002. The study group were identified as having a history of recurrent respiratory tract infections (RRTIs) (≥ 8 episodes/year in < 3-year olds or ≥ 6 episodes/year in ≥ 3-year olds) and an acute LRTI or upper respiratory tract infection (URTI), as diagnosed by a paediatrician and recorded on a medical chart. Exclusion criteria for the study group included acute streptococcal pharyngitis/acute otitis media/community-acquired pneumonia at enrolment, severe concomitant disease, nosocomially-acquired infection, topical/systemic steroid therapy in the 48 hours preceding study enrolment, systemic antibiotic treatment in the 48 hours preceding study enrolment, administration of azithromycin therapy in the week preceding study enrolment, and intramuscular (IM) administration of benzathine penicillin G in the month preceding study enrolment The control group were chosen from otherwise healthy participants undergoing minor surgical treatment during the study period. They were to be of a similar age and gender to the study group, without a history of respiratory tract infection or antibiotic treatment in the 3 months before enrolment Acute M. pneumoniae infection, C. pneumoniae infection, or both was diagnosed if the child had a significant antibody response in paired sera or if the DNA of the bacteria was detected in nasopharyngeal aspirates, or both Participants 560 children, aged 1 to 14 years. 352 had acute respiratory infections and a history of recurrent respiratory tract infections (mean age = 3.6, 57.1% male, 136 with acute M. pneumoniae infection), and 208 were in the control group (mean age = 3.9, 57.2% male, 5 with acute M. pneumoniae infection)
Interventions
Patients were randomised to receive azithromycin (n = 177, 10 mg/kg/day, 3 days/week for 3 weeks) with symptom-specific agents (acetaminophen, 10 mg/kg per dose) or symptom-specific agents alone (n = 175) Outcomes 1. Clinical presentations 2. Bacteriological findings
Notes -
Risk of bias
Item
Authors' judgement Description
Adequate sequence generation? Yes Quote: "All the patients were randomised in a blinded manner with a computerized list, by the only investigator responsible for randomisation." Comment: Randomisation was appropriate
Esposito 2005 (Continued)
Allocation concealment? Yes The enrolment officer was different to the investigator assigned to randomisation. Consequently, the enroller was unaware of which treatment group the participants would be allocated to Blinding? All outcomes Yes Clinical outcome assessor blinded. Although patients and caregivers were not blinded, caregivers were "instructed not to inform the evaluator, who was blinded with respect to randomisation, whether the child had received azithromycin." Quote: "Data entry and statistical analyses were carried out in a blinded manner, with SAS software." Comment: Raw data analyses were also blinded Follow up? All outcomes Yes Quote: "All of the enrolled patients completed the 1-month follow-up evaluation. " Quote: "A total of 339 patients (96.3%) completed the 6-month follow-up evaluation." Comment: A high proportion of participants were followed up
Reporting of participants by allocation group? All outcomes
Yes
The progress of all the children in both groups was described, although at 6 months 13 children were noted to be lost to follow up. The tables of results (both 1-month and 6-month follow ups) account for all available children
Harris 1998
Methods Participants were recruited from 23 centres with a diagnosis of community-acquired pneumonia from 31 January 1994 to 31 May 1995. Inclusion criteria were children with clinically suspected pneumonia based on a radiological finding and the presence of tachypnoea. In addition patients had at least one of the following: fever or history of fever within 24 hours, cough, WCC >= 12000/mm, or chest findings suggestive of pneumonia. Exclusion criteria were hypersensitivity to macrolides, penicillin or betalactam antibiotics, pregnancy or lactation, parenteral therapy required because of severe or multilobar pneumonia, treatment with any other systemic antibiotics within enrolment, evidence of underlying haematological, renal, hepatic or cardiovascular disease, chronic steroid use or concomitant treatment with theophylline, carbamazepine, ergotamine, digitalis glycosides, terfenadine, loratadine or astemizole. Study was a multi-centre, parallel group in which participants were randomised 2:1 to azithromycin or either amoxycillin-clavulanate if under 5 years and erythromycin if over 5 years. The method of randomisation was not described. Participants were blinded to therapy but there was no mention of blinding of clinicians or outcome assessors. There was a description of withdrawals or drop-outs. There was an assessment of compliance by comparing medication bottle weights at beginning and end of study. Participants were evaluated at 4 clinic visits: baseline; study days 2 to 5; study days 15 to 19; and 4 to 6 weeks posttherapy. Laboratory tests were obtained at baseline and on study days 15 to 19. Chest Xrays were obtained at baseline and 4 to 6 weeks post-therapy. Evidence of infection with M. pneumoniae was determined by enzyme-linked immunosorbent assay and defined as either single positive serum IgM (>= 1:10) or 4-fold increase in IgG titre. Clinical response at study days 15 to 19 was classified as: cure, complete resolution of signs and symptoms of pneumonia; improvement, incomplete resolution of signs and symptoms of pneumonia; failure, persistence (or progression) of signs and symptoms of pneumonia after 3 days of therapy or development of new clinical findings consistent with active infection or persistence (or progression) of radiological findings obtained when clinically indicated. Clinical response 4 to 6 weeks post-therapy was classified as follows: cure; complete resolution of signs and symptoms of pneumonia and improvement or resolution of radiographic findings; failure; persistence (or progression) of signs and symptoms of pneumonia after 3 days of therapy or development of new clinical findings consistent with active infection or persistence (or progression) of radiological findings. Bacteriological response was classified as follows: eradication (presumed or proven), elimination of the original organism from the same site during or after completion of therapy and includes cases where repeat specimens were nor obtained and patients considered a clinical cure or improved; persistence, failure to eradicate the organism and includes cases where specimens were not obtainable at the time alternative therapy was instituted and the patient was considered a clinical failure. Adverse events were monitored throughout the study by reported symptoms, physical examinations and laboratory tests. Events were rated by severity (mild, moderate or severe at the discretion of the investigator), organ system and relation to study drug The progress of all randomised children in each group was described, with numbers lost to exclusion and follow up noted
Kogan 2003
Methods Participants with a diagnosis of community-acquired pneumonia were recruited from 1 January 1996 to 1 January 1999. Inclusion criteria were children with a clinical diagnosis radiologically confirmed of presumed bacterial community-acquired pneumonia, eligible for treatment with oral antibiotics and without signs of respiratory insufficiency. Exclusion criteria were history or evidence of chronic pathology of any organ system, chronic pulmonary disease, history of prematurity, treatment with any antibiotics within 5 days prior to enrolment, or known hypersensitivity to beta-lactam antibiotics or macrolides. The study population was divided into 2 groups according to clinical and radiological patterns. One group included those children who presented with signs of classic bacterial pneumonia, with high fever and chest findings of crackles or signs of consolidation, and chest X-rays with segmental, alveolar, or lobar consolidation. The second group included patients with atypical pneumonia, with prominent and frequently paroxysmal cough, variable fever, few clinical signs of consolidation, crackles and wheezing, and chest Xrays with a mixed alveolar-interstitial pattern. Participants with classic pneumonia were randomised to either amoxycillin or azithromycin, whereas participants in the atypical pneumonia were randomly assigned to either azithromycin or erythromycin. The method of randomisation was not described. There was no mention of blinding except for blinding of the radiologist who viewed follow up chest X-rays done on study days 7 and 14. There was a description of withdrawals or drop-outs. There was no assessment of compliance. Outcomes were evaluated at 3 clinic visits, on study days 3, 7 and 14. A chest X-ray was done in each child on study days 7 and 14. Evidence of infection was determined by indirect immunofluorescence (IFI) and enzyme-linked immunosorbent assay to test sera for IgM antibodies to M. pneumoniae. An antibody titre > 1:16 on a single first serum specimen was considered positive for IFI. Clinical response in the classic pneumonia group was defined as proportion of children without fever on day 3 and/or improvement of more than 75% of radiographic baseline findings on study day 7
Participants 110 children aged 1 month to 14 years were enrolled. 4 children developed serious pneumonia in the first 12 hours of enrolment and were excluded from the study (3 from the atypical group and 1 from the classic group). The remaining 106 completed the study. The mean age was 4.9 years and 53 were male. 47 met the criteria for classic pneumonia. 
Yes
The progress of all randomised children in each group was described. Results tables compared outcomes between groups
Ruhrmann 1982
Methods Participants were selected at the children's hospital in Hamburg, Germany. Patients were diagnosed with pneumonia based on CXR. The study compared erythromycin therapy with amoxycillin therapy. The duration of the study was not specified, nor were the inclusion and exclusion criteria. Although the treatment allocation was randomised, there was no blinding of the outcome assessor or the participant. Baseline measurements were recorded using temperature, full blood examination (FBE), CXR and cough presence. Outcome measures were noted over 10 days and were not well-described, with 'clinical improvement' being documented without any clear definition 
Saez-Llorens 1998
Methods Participants were recruited from emergency departments in Dallas and Panama with a diagnosis of community-acquired pneumonia for the period February 1996 to December 1997. Inclusion criteria were tachypnoea, fever, cough, crackles and CXR with changes compatible with pneumonia. Exclusion criteria were hypersensitivity to macrolides or beta-lactam antibiotics, pregnancy, nosocomial pneumonia, use of systemic antibiotics 72 hours prior to recruitment, chronic illness such as HIV, malignancy, cystic fibrosis, haematologic, renal, cardiovascular, hepatic or pulmonary diseases, as well as patients on teofilin, antihistamines, steroids or any medications with potential interaction with macrolides. Study participants were randomised to azithromycin or either amoxycillinclavulanate if under 5 years and erythromycin if over 5 years. A random number list was used and therapy assigned by pharmacy. The study was not blinded. There were 39 drop-outs, although reasons were not specified. There was no assessment of compliance. Clinical outcomes were evaluated on day 2 to 3 and 10 to 25. Baseline measurements were recorded using blood cultures, nasopharyngeal aspirate cultures and PCR for M. pneumoniae and C. pneumoniae. Antibody titres against the 2 microorganisms were evaluated using serology. Additionally, FBE, urea and electrolytes, liver function tests and tuberculin tests were used to assess infection. Clinical response was evaluated as a cure or fail, and clinical cure was defined as complete resolution or evident improvement of all clinical signs and symptoms. Clinical failure was defined as persistent or progressive symptoms after 3 days of treatment 
